Journey Medical (DERM) Insider Cooper Buys 10,000 Shares

Pearce Michael Cooper purchased 10,000 shares of Journey Medical Corporation (DERM) on June 25, 2026. This acquisition was part of a coordinated series of purchases by the company's leadership team, all occurring on the same day and involving the same number of shares.

Broad Insider Activity at Journey Medical

The purchase by Pearce Michael Cooper was not an isolated event. On June 25, 2026, five other insiders also stepped in to buy 10,000 shares each. This group included Toledano Miranda Jayne, Rosenwald Lindsay Md, Smith Justin Adam, and Neil Herskowitz, who actually made two separate purchases of 10,000 shares. None of these transactions were part of a Rule 10b5-1 plan, which is a tool insiders use to set up trades ahead of time to avoid any appearance of using private information. Instead, these appear to be direct market decisions made by the group on the same business day.

Journey Medical Stock Performance

On Saturday, the stock was priced at $6.62. This puts the shares slightly under the 50-day moving average of $7.03 and the 200-day moving average of $6.92. Moving averages help investors see the price trend over time, and trading just below these levels can sometimes indicate a period of consolidation. The stock has seen a wide range over the last year, moving from a low of $4.31 to a high of $9.56. With a beta of 1.10, the stock tends to move slightly more than the overall market.

Recent Earnings and Financial Growth

In its most recent financial reports, Journey Medical showed revenue of $68.18 million. This reflects a growth rate of 23.3%, showing that the company is successfully expanding its sales. However, the company is not yet profitable, reporting a negative return on equity of 23.7% and a net margin of -8.95%. Because it hasn't reached profitability, the company does not have a traditional P/E ratio. The next big update for investors will come when the company reports its next set of earnings on November 11, 2026.

Analysts Set New Price Targets

Wall Street remains optimistic about the company's future. On August 13, 2026, B. Riley Securities reiterated its Buy rating on the stock and set a price target of $15.00. Across the four analysts who cover the stock, the consensus is a Strong Buy. Their average price target is $13.75, which is more than double where the stock is currently trading. These targets are based on the analysts' expectations for the company's drug pipeline and sales growth over the coming year.

About Journey Medical Corporation

Journey Medical is a pharmaceutical company based in Scottsdale, Arizona, that focuses on skin health. It sells several treatments for common conditions like severe acne, rosacea, and fungal infections. Its products include Qbrexza for excessive sweating and Accutane for acne. By specializing in dermatology, the company aims to build a dominant position in a specific niche of the healthcare market. The recent insider buying suggests that the people running the company see value in its current pharmaceutical portfolio.

What's Ahead for Journey Medical Corporation

Investors will likely watch to see if this cluster of insider buying continues or if the company can turn its double-digit revenue growth into positive earnings. The large gap between the current stock price and analyst price targets will also be a point of focus as the November earnings date approaches. As with all insider transaction reports, these trades were disclosed after they occurred and may not reflect the insiders' current outlook on the company.